Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Hepatic resection for metastatic melanoma in The Netherlands survival and prognostic factors

Hepatic resection for metastatic melanoma in The Netherlands survival and prognostic factors Original article 27 Hepatic resection for metastatic melanoma in The Netherlands: survival and prognostic factors a c d Jannemarie de Ridder , Marlies van Walsum , Cornelis Verhoef , b a Iris Nagtegaal , Johannes de Wilt and on behalf of the Dutch Liver Working Group Patients with hepatic metastases of melanoma have a very postoperative mortality. The median follow-up was poor prognosis, with a median overall survival of less than 21 months (range 3–65). The median disease-free 6 months. There are several small heterogeneous studies survival was 11 months (range 0–57) and the median that have shown an association with prolonged survival overall survival was 29 months (range 4–66). Significant in those patients treated with hepatic resection, but the role prognostic factors for overall survival in univariate analysis of surgery remains unclear. We evaluated the safety and were the distribution and number of metastases, as well as efficacy of hepatic resection in a population-based study the type of hepatic resection (major or minor). Hepatic in the Netherlands for patients with metastatic melanoma resection in patients with resectable metastatic melanoma and assessed the factors that could affect disease-free is safe and might be associated with a prolonged survival and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Melanoma Research Wolters Kluwer Health

Hepatic resection for metastatic melanoma in The Netherlands survival and prognostic factors

de Wilt, Johannes
Melanoma Research , Volume 23 (1) – Feb 1, 2013
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/hepatic-resection-for-metastatic-melanoma-in-the-netherlands-survival-drU6U0RTy3

References (52)

Copyright
© 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
ISSN
0960-8931
eISSN
1473-5636
DOI
10.1097/CMR.0b013e32835b70c8
pmid
23164992
Publisher site
See Article on Publisher Site

Abstract

Original article 27 Hepatic resection for metastatic melanoma in The Netherlands: survival and prognostic factors a c d Jannemarie de Ridder , Marlies van Walsum , Cornelis Verhoef , b a Iris Nagtegaal , Johannes de Wilt and on behalf of the Dutch Liver Working Group Patients with hepatic metastases of melanoma have a very postoperative mortality. The median follow-up was poor prognosis, with a median overall survival of less than 21 months (range 3–65). The median disease-free 6 months. There are several small heterogeneous studies survival was 11 months (range 0–57) and the median that have shown an association with prolonged survival overall survival was 29 months (range 4–66). Significant in those patients treated with hepatic resection, but the role prognostic factors for overall survival in univariate analysis of surgery remains unclear. We evaluated the safety and were the distribution and number of metastases, as well as efficacy of hepatic resection in a population-based study the type of hepatic resection (major or minor). Hepatic in the Netherlands for patients with metastatic melanoma resection in patients with resectable metastatic melanoma and assessed the factors that could affect disease-free is safe and might be associated with a prolonged survival and

Journal

Melanoma Research – Wolters Kluwer Health

Published: Feb 1, 2013

There are no references for this article.